SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodefidiency virus type 1 Tat vaccine

Journal of Medical Primatology

Volumn 29, Issue 3-4, 2000, Pages 193-208

  Cafaro, Aurelio ^a   Caputo, Antonella ^b   Maggiorella, Maria Teresa ^a   Baroncelli, Silvia ^a   Fracasso, Claudio ^a   Pace, Monica ^a   Borsetti, Alessandra ^a   Sernicola, Leonardo ^a   Negri, Donatella R M ^a   Ten Haaft, Peter ^c   Betti, Monica ^b   Michelini, Zuleika ^a   Macchia, Iole ^a   Fanales Belasio, Emanuele ^a   Belli, Roberto ^a   Corrias, Franco ^a   Buttò, Stefano ^a   Verani, Paola ^a   Titti, Fausto ^a   Ensoli, Barbara ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

Correlation; CTL; Macaque; Preventive; Therapeutic

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSACTIVATOR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DRUG EFFICACY; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MACACA; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; VACCINATION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; MACACA; MACACA FASCICULARIS; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0033807492     PISSN: 00472565     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0684.2000.290313.x     Document Type: Article

References (68)

1. AIDS vaccine development in primate models
2. Perforin, Fas/Fas ligand, and TNFα pathways as specific and by-stander killing mechanisms of hepatitis C virus-specific human CTL
3. The trans-activator gene of human T lymphotropic virus type III (HTLV-III)
4. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques
5. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression: Implications for AIDS-Kaposi's sarcoma pathogenesis
6. The Tat protein of human immunodeficiency virus type- 1, a growth factor for AIDS Kaposi's sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence
7. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the a5b3 integrins by mobilizing sequestered basic fibroblast growth factor
8. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of bFGF and avb3 integrin that are required for Tat activity
9. Comparison of in vitro and in vivo infectivity of different clade B HIV-1 envelope chimeric simian/human immunodeficiency viruses in Macaca mulatta
10. Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: Consequences of challenge
11. Why we do not have an HIV vaccine and how can we make one?
12. Control of SHIV-89.6P infection of cynomolgus Monkeys by HIV-1 Tat protein vaccine
13. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
14. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment
15. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease
16. HIV-1 Tat protein exits from cells via a leader-less secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region
17. Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 Tat protein
18. Cytotoxic T lymphocytes do not appear to select for mutations in an immunodominant epitope of simian immunodeficiency virus gag
19. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
20. A recombinant prime, peptide boost vaccination strategy can focus the immune response on to more than one epitope even though these may not be immunodominant in the complex immunogen
21. Evolution of a simian immunodeficiency virus pathogen
22. Tat protein of HIV-1 stimulates growth of AIDS-Kaposi's sarcoma-derived cells
23. Release, uptake, and effects of extracellular HIV-1 Tat protein on cell growth and viral transactivation
24. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma development
25. The monkey's got AIDS: What now for live AIDS vaccine?
26. Pokeweed mitogen-stimulated peripheral blood mononuclear cells from at-risk seronegative subjects produce in vitro HIV-1-specific antibodies
27. Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells
28. + T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus-1 Tat protein: An immune response to human herpesvirus-8 infection?
29. The transactivator gene of HTLV-III is essential for virus replication
30. Cellular uptake of the Tat protein from human immunodeficiency virus
31. Cytotoxic T lymphocyte activity in children infected with HIV
32. Immunization of chimpanzees confers protection against challenge with human immunodeficiecy virus
33. Anti-HIV cellular immunity: Recent advances towards vaccine design
34. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains
35. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNFα), and TNF-β when they encounter their target antigens
36. + lymphocyte depletion in rhesus monkeys
37. Importance of the nef gene for maintenance of high virus loads and for development of AIDS
38. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide
39. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
40. Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus
41. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein
42. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection
43. Vaccination with Rev and Tat against AIDS
44. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact
45. Detection of HIV-1-specific CTLs in the semen of HIV-infected individuals
46. + cytotoxic T lymphocyte-mediated lysis
47. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo
48. A chimeric simian/human immunodeficiency virus type 1 isolate env causes in AIDS-like disease after in vivo passage in rhesus monkeys
49. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1
50. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors
51. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein
52. A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey
53. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: Effects of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 virus
54. Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness
55. A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-immunodeficiency virus-infected macaques
56. Live-attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac 251 in Cynomolgus monkeys
57. HIV-1 Rev and Tat specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS
58. Cytotoxic T lymphocyte response against multiple simian immunodeficiency virus (SIV) proteins in SIV-infected macaques
59. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1
60. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120
61. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence
62. +) T cells in chronic HIV infection are antigen specific
63. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge
64. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS
65. Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum an adjuvant to antiretroviral tritherapy
66. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: A rationale for the use of Tat toxoid as an HIV-1 vaccine
67. + T lymphocytes